

Date: 10/11/2023

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Sub: - Outcome of the Board Meeting held on 10th November, 2023

Company Scrip Code: 532167

Dear Sir,

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please note that the Board in their meeting held on 10th November, 2023 has considered and approved the following business:

Unaudited Financial Results of the Company along with Statement of Assets and Liabilities, Cash Flow Statement and Limited Review Report for the Quarter and half year ended on 30th September, 2023.

The aforesaid board meeting commenced at 04:00 P.M. and concluded at 04:50 P.M.

This is for your information and record.

Thanking You,

Yours faithfully,
For **Omkar Pharmachem Limited**

AS

Bhawani Shankar Goyal
(Managing Director)
DIN: 03255804



Address: House No. - 155/2, First Floor, Gali No - 2
Near Gurudwara, Govindpuri, Kalkaji- 110019
Delhi

Enc: a/a

ॐ Omkar Pharmachem Ltd.

Statement of Standalone Unaudited Financial Results for the Quarter and Six Months ended 30th September, 2023							
(Rs. in lakhs except per share data)							
Sr. No.	Particulars	Quarter Ended On			Six Months Ended On		Year Ended On
		30-09-2023	30-06-2023	30-09-2022	30-09-2023	30-09-2022	31-03-2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Part-I							
1	Income from operations						
	a) Net Sales/ Income from Operations	0.00	0.00	0.00	0.00	0.00	0.00
	b) Other Operating Income	13.50	13.50	13.50	27.00	27.00	54.00
		13.50	13.50	13.50	27.00	27.00	54.00
2	Other Income	0.00	0.00	0.00	0.00	0.00	0.30
3	Net Total Income	13.50	13.50	13.50	27.00	27.00	54.30
4	Expenses						
	a) Cost of material consumed	0.00	0.00	0.00	0.00	0.00	0.00
	b) Purchase of Stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in Inventories of Finished Goods, WIP and Stock-in trade	0.00	0.00	0.00	0.00	0.00	0.00
	d) Employee benefits expenses	3.70	2.94	4.37	6.64	8.73	13.87
	e) Finance Cost	0.00	0.00	0.00	0.00	0.00	4.63
	f) Depreciation and Amortization Expenses	0.14	0.06	0.07	0.20	0.14	0.27
	g) Other Expenses	0.61	5.67	1.38	6.28	5.88	9.08
	Total Expenses	4.45	8.67	5.82	13.12	14.75	27.85
5	Profit(Loss) from operations before						
	Exceptional Items & Taxes (3-4)	9.05	4.83	7.68	13.88	12.25	26.45
6	Exceptional items:	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit(Loss) before Tax (5+6)	9.05	4.83	7.68	13.88	12.25	26.45
8	Tax Expense	0.00	0.00	0.00	0.00	0.00	6.67
9	Profit(Loss) for the period (7-8)	9.05	4.83	7.68	13.88	12.25	19.78
10	Other Comprehensive Income (Expense)	0.00	0.00	0.00	0.00	0.00	0.00
11	Total Comprehensive Income for the period (9+10)	9.05	4.83	7.68	13.88	12.25	19.78
12	Paid up Equity Share Capital (Face Value Rs. 10/-each)	1008.37	1008.37	1008.37	1008.37	1008.37	1008.37
13	Other Equity	-	-	-	-	-	(104.00)
14	Earning Per Share (before & after extraordinary items) (of Rs. 10 each) (not annualised) Basic and diluted Rs.	0.0898	0.0479	0.0762	0.1376	0.1215	0.1962

94-



3D Omkar Pharmachem Ltd.

Statement of Assets and Liabilities as at 30th September, 2023		(Rs. in lakhs)	
Particulars	As at 30-09-2023	As at 31-03-2023	
	(Unaudited)	(Audited)	
ASSETS			
Non-current Assets			
a) Property, plant and equipment	0.93	0.37	
b) Capital work-in-progress	0.00	0.00	
c) Goodwill on consolidation	0.00	0.00	
d) Other intangible assets	0.17	0.00	
e) Intangible assets under development	0.00	0.00	
f) Financial assets	0.00	0.00	
i) Investments			
a) Investment in associate	0.00	0.00	
b) Investments in joint ventures	0.00	0.00	
c) Other Investments	930.00	930.00	
ii) Other Financial Assets	0.00	0.00	
g) Deferred tax assets (net)	16.39	16.39	
h) Other non current assets	0.00	0.00	
Total Non-current Assets	947.49	946.76	
Current Assets			
a) Inventories	0.00	0.00	
b) Financial assets			
i) Other Investments	0.00	0.00	
ii) Trade receivables	15.66	12.96	
iii) Cash and cash equivalents	8.18	13.27	
iv) Bank balances other than iii) above	0.00	0.00	
v) Other financial assets	0.00	0.00	
c) Other current assets	0.00	0.00	
Total Current Assets	23.84	26.23	
Total Assets	971.33	972.99	
EQUITY AND LIABILITIES			
Equity			
a) Equity share capital	1008.37	1008.37	
b) Other equity : Reserve and Surplus	-90.12	-104.00	
Equity attributable to the owners of the company	918.25	904.37	
Non-controlling interests	0.00	0.00	
Total Equity	918.25	904.37	
Non-current liabilities			
Financial liabilities			
a) Borrowings	0.00	0.00	
b) Provisions	0.00	0.00	
c) Deferred tax liabilities(Net)	0.00	0.00	
Total Non-current Liabilities	0.00	0.00	
Current Liabilities			
Financial liabilities			
i) Borrowings	49.14	62.14	
ii) Trade Payables	1.85	4.14	
iii) Other financial liabilities	0.00	0.00	
b) Provisions	0.43	0.43	
c) Other current liabilities	1.66	1.91	
Total-current Liabilities	53.08	68.62	
Total Liabilities	53.08	68.62	
Total Equity and Liabilities	971.33	972.99	

By -



ॐ Omkar Pharmachem Ltd.

Unaudited Cash flow statement for the half year ended on 30th September, 2023

(Rs. in lakhs)

Particulars	Half year ended	Half year ended
	30th September, 2023	30th September, 2022
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before tax and exceptional items	13.88	12.25
Adjustment For :		
Depreciation	0.20	0.14
Net interest paid (received)	0.00	0.00
Operating profit before working capital change	14.08	12.39
Adjustment For :		
Trade and other receivables	(2.70)	(7.56)
Trade and other payable	(2.54)	0.16
Cash Generated from operation	8.84	4.99
Cash flow before extra ordinary items	0.00	0.00
(Less) Income Tax Paid including Advance Tax/TDS less refund	0.00	0.00
NET CASH FLOW FROM OPERATING ACTIVITIES	8.84	4.99
B. CASH FLOW FROM INVESTING ACTIVITIES		
Sale of Property, plant and equipment (Land)	0.00	0.00
Sale of Investment	0.00	0.00
Purchase of Property, plant and equipment	(0.93)	0.00
NET CASH USED IN INVESTING ACTIVITIES	(0.93)	0.00
C. CASH FLOW FROM FINANCIAL ACTIVITIES		
Interest received/(paid)	0.00	0.00
Short Term Borrowings	(13.00)	(15.00)
NET CASH FLOW FROM FINANCIAL ACTIVITIES	(13.00)	(15.00)
TOTAL CASH FLOW	(5.09)	(10.01)
NET INCREASE/DECREASE IN CASH AND CASH EQUIVALENTS :		
Opening Cash and Cash Equivalents	13.27	21.14
Closing Cash and Cash Equivalents	8.18	11.13
NET INCREASE/DECREASE IN CASH AND CASH EQUIVALENTS	(5.09)	(10.01)

Notes:

1. The above results have been reviewed by the Audit committee & approved by the Board of Directors at their respective meeting held on 10-11-2023
2. Corrospounding previous period figures are regrouped/rearranged wherever necessary, to make them comparable
3. The Financial Result for the Quarter and Half year ended on 30-09-2023 has been prepared in accordance with IND-AS specified under section 133 of the Companies Act and rules made thereunder.
4. The IND-AS regarding segment reporting is not applicable to the company.

Date : 10-11-2023
Place: Ahmedabad



By order of the Board

Bh

(Bhawani Shankar Goyal)

Managing Director

DIN No. 03255804

H House No.155/2, First Floor, Gali No - 2, Near
D Gurudwara, Govindpuri, Kalkaji, Delhi-110019



Limited Review Report to the Board of Directors of **Omkar Pharmachem Limited**
for quarter and half year ended on 30th September, 2023


We have reviewed the accompanying statement of unaudited financial results of **Omkar Pharmachem Limited** for quarter and half year ended on 30th September, 2023.

This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and; thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in




terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rajesh J. Shah & Associates
Chartered Accountants
FRN 108407W



CA Rajesh J. Shah
Partner
M. NO. 040268



Place: Ahmedabad
Date : 10/11/2023

UDIN : **23040268BGWVRX1096**